Sugi Predict

Sugi Predict / Compounds / SCHEMBL5069414

SCHEMBL5069414

SCHEMBL5069414

Cc1ccccc1S(=O)(=O)N1CCc2c[nH]nc2C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ MAPK1 P28482 1/20 0.42
▸ LMNA P02545 2/20 0.41
▸ CTSG P08311 1/20 0.40
▸ CMA1 P23946 1/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ TP53 P04637 1/20 0.39
▸ ESR1 P03372 2/20 0.38
▸ ESR2 Q92731 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ PLA2G1B P04054 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ ATG4B Q9Y4P1 1/20 0.38
▸ NR3C1 P04150 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5067933 0.81 CD4 (0.52) KMT2AMEN1HTT
SCHEMBL5069904 0.79 MCOLN3 (0.56) KMT2AL3MBTL1MAPK1MEN1SMN1; SMN2
SCHEMBL5070054 0.78 AKR1C3 (0.50) KMT2AMEN1SMN1; SMN2CYP3A4CYP2C19
SCHEMBL5069905 0.73 TSHR (0.49) KMT2ALMNAMEN1HPGDRAB9A
SCHEMBL12656055 0.73 CYP3A4 (0.52) KMT2AL3MBTL1LMNACTSGCMA1
SCHEMBL5369302 0.72 CYP3A4 (0.59) KMT2AL3MBTL1LMNACTSGCMA1
SCHEMBL2805150 0.70 ALOX5AP (0.39) KMT2AL3MBTL1MAPK1LMNACTSG
SCHEMBL4985357 0.70 CTSG (0.41) KMT2AL3MBTL1MAPK1LMNACTSG
SCHEMBL26654877 0.70 PKM (0.53) KMT2AL3MBTL1LMNAMEN1SMN1; SMN2
SCHEMBL14818738 0.69 TSHR (0.71) KMT2AL3MBTL1MAPK1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7435820-B2 Substituted tetrahydro-1H-pyrazolo [3,4-c]pyridines compositions comprising them, and use AVENTIS PHARMA S.A. (FR) 2008-10-14 — — US disclosed
US-7109340-B2 Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use AVENTIS PHARMA S.A. (FR) 2006-09-19 — — US disclosed
US-20060199837-A1 SUBSTITUTED TETRAHYDRO-1H-PYRAZOLO [3,4-C]PYRIDINES COMPOSITIONS COMPRISING THEM, AND USE AVENTIS PHARMA S.A. (FR) 2006-09-07 — — US disclosed
US-20050096345-A1 Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use AVENTIS PHARMA S.A. (FR) 2005-05-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199837-A1 SUBSTITUTED TETRAHYDRO-1H-PYRAZOLO [3,4-C]PYRIDINES COMPOSITIONS COMPRISING THEM, AND USE BRD4, TP53, HCCS KMT2A 2122/4885L3MBTL1 3427/4885MAPK1 1500/4885
US-20050096345-A1 Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use BRD4, TP53, HCCS KMT2A 2265/4885L3MBTL1 3700/4885MAPK1 1293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.